📓 Final PECATI trial supports PEMBRO + LENVATINIB in pretreated met B3 thymoma & thymic Ca.
📊 mINV-PFS: 22 mo | OS: 40 mo
🚀 Can IO, ADCs & bispecifics move to 1st line?
💪🏻 More academic & pharma collaboration is needed in rare thoracic malignancies!
🔗 authors.elsevier.com/a/1o6FL…
Martin Reck (@MartinReck2) presented MDT-BRIDGE at ESMO 2026, where 3 in 4 patients with resectable or borderline resectable NSCLC reached resection after neoadjuvant durvalumab plus chemotherapy. Among the authors are our faculty members Nicolas Girard (@nicogirardcurie) and Andrea Filippi (@AndrearicFili).
🔬 MDT-BRIDGE: neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable NSCLC, n=142
📊 Resection rate 74.6% (descriptive)
📊 R0 resection 96.2% (of resected patients)
⚠️ Gr 3-4 AEs, adjuvant vs consolidation phase 7.4% vs 17.4%
⚠️ Descriptive primary endpoint, with no formal hypothesis test
Compare the surgery and chemoradiotherapy pathways in our article.
@myESMOlungsummit.org/articles/neoa…
On a beautiful crisp autumnal London morning, am reflecting on the major practice-changing and development datasets presented @myESMO#ESMO26, the strong @royalmarsdenNHS & @ICR_London faculty leadership, & above all the global friends & colleagues who are
making a difference
Our SCLC symposium at ESMO 2026 in Madrid kept the Salamanca Auditorium full to the last talk yesterday, and the overflow room as well. Thank you all for coming.
From Solange Peters @peters_solange, Martin Reck @MartinReck2, Giannis Mountzios @g_mountzios and Noemí Reguart @NReguart: thank you for staying with us through all 4 talks.
The full recording is online now, with all 4 slide decks and your CME certificate. Free for healthcare professionals 🙂
Recording, slides and certificate: lungsummit.org/featured/sclc…#ESMO26#SCLC#LungCancer
🔥 Outstanding piece of work published today in Nature Medicine!
Huge congratulations to @MartinReck2 ,@NadalErnest , @DoctorJSpicer and @AndrearicFili , and the entire MDT-BRIDGE team on this important publication! 👏👏
The phase II MDT-BRIDGE trial, investigating neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable NSCLC, tackles a clinically relevant question: how can we push the boundaries of multidisciplinary treatment and offer more patients a chance of curative-intent therapy?
This is exactly the kind of collaborative clinical research we need: challenging established boundaries, asking meaningful questions, and ultimately striving to improve outcomes for our patients.
Congratulations to everyone involved! 👏
🔗 nature.com/articles/s41591-0…
Happy to continue sharing exciting advances in lung cancer research as an #ESMOAmbassadors#ESMO26#NatureMedicine#LungCancer#NSCLC#ThoracicOncology#Immunotherapy#ClinicalResearch#MultidisciplinaryCare#CancerResearch
Thank you, Madrid. Thank you to everyone who joined our SCLC symposium at ESMO 2026, and to Solange Peters, Martin Reck, Giannis Mountzios and Noemí Reguart. Thank you, too, for your questions, from the room and sent ahead. Next: ILCS 2026 in Lausanne on 13 November. We hope to see you there.
@peters_solange@MartinReck2@g_mountzios@NReguart
Programme and faculty: lungsummit.org/featured/sclc…#ESMO26#SCLC#LungCancer
#ESMO26 : A great brainstorming summit on #SCLC organized by @LungSummit in a fully packed auditorium+overflow following yesterday’s announcement of DeLlphi-305;
➡️ The chemoIO landscape in 1L @MartinReck2
➡️ T-cell engager clinical development @peters_solange
➡️ Management οf CRS and ICANS @g_mountzios
➡️ Sequencing and combinations @NReguart
A heartfelt 🙏 for your presence, interaction and tons of questions!!!
#ESMOAmbassadors
We look forward to welcoming you in the Salamanca Auditorium during #ESMO26 in Madrid.
Join @g_mountzios, @NReguart, @peters_solange and @MartinReck2 for the latest advances in SCLC.
📅 25th October 2026
🕐 13:00 – 14:30
📍Salamanca Auditorium, Hall 10 – IFEMA Madrid, Spain
We look forward to welcoming you in the Salamanca Auditorium during #ESMO26 in Madrid.
Join @g_mountzios, @NReguart, @peters_solange and @MartinReck2 for the latest advances in SCLC.
📅 25th October 2026
🕐 13:00 – 14:30
📍Salamanca Auditorium, Hall 10 – IFEMA Madrid, Spain